Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells $17,766.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 987 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $17,766.00. Following the completion of the sale, the vice president directly owned 38,613 shares of the company’s stock, valued at approximately $695,034. This represents a 2.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Friday, May 22nd, David Foehr sold 862 shares of CeriBell stock. The shares were sold at an average price of $18.80, for a total transaction of $16,205.60.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The shares were sold at an average price of $17.80, for a total transaction of $81,168.00.

CeriBell Price Performance

Shares of CBLL stock opened at $18.67 on Friday. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The stock has a market cap of $708.34 million, a PE ratio of -11.45 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The firm’s 50 day moving average price is $19.07 and its two-hundred day moving average price is $19.34.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The business had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. As a group, analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current year.

Hedge Funds Weigh In On CeriBell

Institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its holdings in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the period. Strs Ohio acquired a new position in shares of CeriBell in the 1st quarter valued at $27,000. CWM LLC grew its holdings in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the period. Finally, Larson Financial Group LLC grew its holdings in shares of CeriBell by 1,403.1% in the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock valued at $63,000 after buying an additional 2,680 shares during the period.

Wall Street Analysts Forecast Growth

CBLL has been the topic of a number of recent analyst reports. Canaccord Genuity Group reduced their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.